Teacher Retirement System of Texas Sells 2,628 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Teacher Retirement System of Texas lowered its stake in 10x Genomics, Inc. (NASDAQ:TXGFree Report) by 40.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,846 shares of the company’s stock after selling 2,628 shares during the period. Teacher Retirement System of Texas’ holdings in 10x Genomics were worth $215,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of 10x Genomics by 3.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 924,832 shares of the company’s stock valued at $51,754,000 after buying an additional 32,709 shares in the last quarter. Vestmark Advisory Solutions Inc. bought a new stake in shares of 10x Genomics during the 4th quarter valued at $4,332,000. M&T Bank Corp bought a new stake in shares of 10x Genomics during the 4th quarter valued at $252,000. New York Life Investment Management LLC bought a new stake in shares of 10x Genomics during the 4th quarter valued at $626,000. Finally, Victory Capital Management Inc. boosted its holdings in shares of 10x Genomics by 24.6% during the 4th quarter. Victory Capital Management Inc. now owns 12,738 shares of the company’s stock valued at $713,000 after buying an additional 2,515 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Price Performance

Shares of TXG opened at $22.41 on Friday. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -10.05 and a beta of 1.94. 10x Genomics, Inc. has a 1 year low of $21.74 and a 1 year high of $63.57. The business’s 50 day simple moving average is $29.55 and its 200-day simple moving average is $40.36.

10x Genomics (NASDAQ:TXGGet Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $141.01 million for the quarter, compared to analysts’ expectations of $142.24 million. 10x Genomics had a negative return on equity of 30.85% and a negative net margin of 42.20%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.44) EPS. On average, sell-side analysts expect that 10x Genomics, Inc. will post -1.55 earnings per share for the current year.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 4,660 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $44.00, for a total transaction of $205,040.00. Following the sale, the chief executive officer now owns 842,900 shares in the company, valued at approximately $37,087,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other 10x Genomics news, CFO Justin J. Mcanear sold 2,936 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $71,344.80. Following the sale, the chief financial officer now owns 146,203 shares in the company, valued at $3,552,732.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 4,660 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the sale, the chief executive officer now owns 842,900 shares in the company, valued at approximately $37,087,600. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,560 shares of company stock worth $494,210. Company insiders own 10.03% of the company’s stock.

Wall Street Analyst Weigh In

TXG has been the subject of several recent analyst reports. TD Cowen lowered 10x Genomics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $57.00 to $32.00 in a research report on Wednesday, May 1st. Stifel Nicolaus lowered their price target on 10x Genomics from $63.00 to $53.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Deutsche Bank Aktiengesellschaft decreased their target price on 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. Canaccord Genuity Group decreased their target price on 10x Genomics from $65.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 29th. Finally, Barclays decreased their target price on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

Read Our Latest Stock Analysis on TXG

About 10x Genomics

(Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Articles

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGFree Report).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.